Clinical trials: Moderate Plaque Psoriasis
Moderate to Severe Plaque Psoriasis
A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 injection in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT06875934
- Testing
- SHR-1139 Injection
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Plaque Psoriasis
Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
The primary purpose of this study is to assess efficacy, safety and tolerability of a 2 mL pre-filled auto-injector (AI) of 300 mg secukinumab in patients with moderate to severe plaque psoriasis
- Trial name
- MATURE (NCT03589885)
- Testing
- Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe
- Where
- 22 sites in United States, Canada and 4 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis
The purpose of this research study is to see how well the medication Alefacept (Amevive®) works for continuous treatment of chronic plaque psoriasis.
- Trial name
- NCT00655564
- Testing
- Alefacept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Wake Forest University
Actively Extending Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate different dose levels of IMO-3100 compared to placebo administered for 4 weeks to patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01622348
- Testing
- IMO-3100 at 0.16 mg/kg, Saline for Injection, IMO-3100 at 0.32 mg/kg
- Where
- 13 sites in United States
- Volunteers
- 44 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Psoriasis
An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis
The purpose of this study is to compare the efficacy and safety of CNTO 1275 to etanercept in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT00454584
- Testing
- CNTO 1275 45 mg, CNTO 1275 90 mg, Etanercept 50 mg
- Volunteers
- 903 people
- Sponsor
- Centocor, Inc.
Psoriasis
An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis
This Phase 3 multicenter, randomized, placebo-controlled, double-blind study is designed to evaluate the efficacy and safety of apremilast in subjects with moderate to severe genital psoriasis (modified sPGA-G ≥3, moderate or…
- Trial name
- DISCREET (NCT03777436)
- Testing
- Apremilast
- Where
- 52 sites in United States, Belgium and 5 more
- Volunteers
- 289 people
- Sponsor
- Amgen
Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
- Trial name
- NCT03897075
- Testing
- Tildrakizumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 99 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis, Eczema
A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features
Emerging evidence indicates that psoriasis and eczema can coexist in the same patient, with reported co-prevalence rates ranging from 0.17% to 20%, suggesting that these conditions may represent a disease spectrum-referred to as…
- Conditions
- Psoriasis, Eczema, JAK Inhibitor
- Trial name
- NCT06999941
- Testing
- Deucravacitinib 6mg po qd
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xi Tan
Psoriasis
Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis
This is a 12 week bilateral study, consisting of 6 weeks of treatment and 6 weeks of follow-up. The purpose of the study is to compare the safety and effectiveness of combining and then following a high potency topical…
- Trial name
- NCT00769184
- Testing
- Corticosteroid, LCD
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- NeoStrata Company, Inc.
Plaque Psoriasis
A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
The primary objective of this study is to determine the efficacy and safety of 074-6751 Lotion applied twice daily for four weeks (28 days) in clinical subjects with moderate plaque psoriasis.
- Trial name
- NCT03167515
- Testing
- 074-6751 Lotion
- Where
- 5 sites in United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Ferndale Laboratories, Inc.
Parapsoriasis
A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.
This study will evaluate the clinical efficacy, the patients quality of life, and safety of oral apremilast 30 mg twice daily (BID) compared to placebo, in adult patients with moderate plaque psoriasis during the 16 week Placebo…
- Trial name
- UNVEIL (NCT02425826)
- Testing
- Apremilast
- Where
- 26 sites in United States
- Volunteers
- 221 people
- Sponsor
- Amgen
Plaque Psoriasis
Bee Venom Phonophoresis on Mild to Moderate Localized Plaque Psoriasis on Knee Joint
Chronic plaque psoriasis, or psoriasis vulgaris, is a chronic inflammatory skin disease characterized by well demarcated, erythematous, scaly plaques on the extensor surfaces of the body and scalp.
- Trial name
- NCT06106230
- Testing
- Bee venom phonophoresis
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- MTI University
Plaque Psoriasis
A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.
- Trial name
- IXORA-R (NCT03573323)
- Testing
- Ixekizumab, Guselkumab
- Where
- 124 sites in United States, Canada and 1 more
- Volunteers
- 1,027 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: Does ESK-001 reduce the severity of people's psoriasis? How safe is ESK-001 in…
- Trial name
- ONWARD2 (NCT06588738)
- Testing
- Envudeucitinib, Apremilast
- Where
- 124 sites in United States, Austria and 10 more
- Volunteers
- 862 people
- Sponsor
- Alumis Inc
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
This was an observational, prospective primary data collection study. The duration of observation was 2 years after study enrolment date.
- Conditions
- Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
- Trial name
- PROMPT (NCT05155098)
- Testing
- secukinumab
- Where
- 10 sites in Thailand
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis of the scalp.
- Trial name
- STYLE (NCT03123471)
- Testing
- Apremilast
- Where
- 45 sites in United States, Canada
- Volunteers
- 303 people
- Sponsor
- Amgen
Psoriasis
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) for the treatment of moderate to severe chronic plaque psoriasis in adult patients.
- Trial name
- NCT02684370
- Testing
- risankizumab, ustekinumab
- Volunteers
- 560 people
- Sponsor
- AbbVie
Psoriasis
A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis
- Trial name
- NCT06701513
- Testing
- Deucravacitinib
- Where
- 48 sites in France, Switzerland
- Volunteers
- 350 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis
This study is a comparison between Clobetasol Propionate Spray and Clobetasol Propionate Ointment with Regard to Efficacy, Safety, Subject Satisfaction and Duration of Response in Moderate to Severe Stable Plaque Psoriasis.
- Trial name
- NCT00733954
- Testing
- clobetasol propionate spray, clobetasol propionate ointment
- Where
- 6 sites in United States
- Volunteers
- 250 people
- Sponsor
- Galderma R&D
Psoriasis
Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery System
This is an observational pilot study comparing triamcinolone acetonide injections with the investigational Med-jet needle-free drug-delivery system as an alternative to using a conventional syringe and needle in patients with…
- Trial name
- NCT04410237
- Testing
- Med-Jet, Traditional Syringe
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University Hospitals Cleveland Medical Center